Linzess TV Commercials

Overview Creative Audience Outcomes Ads

Score Card

Data available through 12/22/2024

11/22/202412/22/2024

Total Creatives

National Airings

1,088

Spend Rank

#458

Airing Rank

#888

National TV Spend

$000,000

Impressions

000,000

Linear SOV

00.00%

Streaming SOV

00.00%

Daily Impressions & Spend Activity

Top Streaming Publishers

This is a profile preview from the iSpot platform

About

Request a demo to track TV ad campaigns for Linzess. Competing brands in the Pharmaceutical & Medical: Rx: Bladder & Gastrointestinal industry include Xifaxan, HUMIRA [Crohn's/Colitis], ENTYVIO, Nexium Rx, and Myrbetriq. Linzess ads feature products in categories including Gas, Pressure and Bloating. You can connect with Linzess on Facebook and YouTube or by phone at 1-800-LINZESS.

Linzess Creative Assessment

Get a Demo

Ad effectiveness starts with the creative, which is why iSpot's Creative Assessment solutions provide fast, actionable insights into the effectiveness and emotional impact of video ads. Brands can objectively measure and benchmark ad performance against competitive and customizable norms while gaining deeper insights through viewer verbatim comments that explain the "why" behind the scores. Using iSpot's Creative Assessment in both pre-market and in-market stages, brands can evaluate creative strengths and weaknesses, make data-driven adjustments, and ultimately improve ad effectiveness while reducing time and spend on creative development.

Linzess TV Spot

000(Nor) Likeability Score
Secure Top Emotion
000(Nor) Purchase Intent
Secure Single Best Thing

Second-by-Second Analysis

Emos

Representative Verbatims

Viewer's Voice

Normal: Fitness Class: $30 for 90 Days

000(Nor) Likeability Score
Secure Top Emotion
000(Nor) Purchase Intent
Secure Single Best Thing

Yes: Travel

000(Nor) Likeability Score
Secure Top Emotion
000(Nor) Purchase Intent
Secure Single Best Thing

Had It Up to Here

000(Nor) Likeability Score
Secure Top Emotion
000(Nor) Purchase Intent
Secure Single Best Thing

To learn about Linzess TV ad testing results, request a demo.

Linzess Audience Measurement

Get a Demo

iSpot empowers advertisers with real-time, second-by-second visibility into every ad across screens, helping optimize media strategies and cut excess frequency and waste. With a robust catalog of over 2.5 million creatives and data from 83 million smart TVs, plus integrations with 400+ streaming platforms and DSPs, iSpot delivers fast, accurate and actionable analytics on both campaign performance and competitor strategies. By measuring impressions, airings, and attention across all viewing environments, advertisers can eliminate blind spots and gain a competitive edge through reliable benchmarking against brands like Xifaxan, HUMIRA [Crohn's/Colitis], ENTYVIO, Nexium Rx, and Myrbetriq.

Media Measurement

Spend SOV

00.00%

Household Impressions

00,000

Local Impressions

00,000

OOH Impressions

00,000

P18+ Impressions

00,000

Streaming Impressions

00,000

Streaming SOV

00.00%

Streaming Benchmark

000

Unified Measurement

Streaming Impressions Overlap with Linear

00,000

Streaming Reach

00.00%

Streaming Reach Overlap

00.00%

Streaming Average Frequency

00.00

Streaming Frequency Overlap with Linear

00.00

Attention Analytics

Attention Index

000

Interruption Rate

00.00%

To learn about Linzess TV ad testing results, request a demo.

Linzess Business Outcomes

Get a Demo

iSpot enables advertisers to connect TV and streaming ad exposure directly to key business outcomes like in-store traffic, website visits, and purchases. By mapping campaign data to first- and third-party sources—such as location, intent, sales, and both online and offline conversions—advertisers can avoid wasting spend on ads that don't drive results. iSpot's real-time attribution technology makes it easy to optimize campaigns across platforms for maximum ROAS, ensuring every dollar works harder.

Conversion Events

0,000,000

Impressions

0,000,000

Conversion Rate

00.00%

Cost Per Unit (CPU)

$0,000

Lift

00.00%

Exposed Rate

0.000%